Loading…
TAME hasn't finished. Existing cohorts mix diabetic and non-diabetic. The pop-culture case is ahead of the trial case.
Healthy-adult metformin trials are scarce; TAME is ongoing; pop-culture longevity case overruns data.
Our read is Limited Research. The mechanistic story is plausible and the early signals are interesting, but the human outcome data is thin: a largely speculative evidence base (36/100) and only thin support (38% consensus). At $10/month, taking metformin off-label for longevity is a bet on preliminary science rather than a settled recommendation.
Pulled the public claims about taking metformin off-label for longevity from the proponents circulating the claim and weighed them against the more cautious voices (a tracked voice and a tracked voice), then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Talk to your doctor. This carries medium risk: interactions, contraindications, and dose sensitivity all matter, so taking metformin off-label for longevity is not a casual decision. Loop in a clinician who can see your full history before starting.
A well-designed human outcome trial — the kind that currently does not exist — demonstrating benefit at the doses people actually use.
Benefits hold across the populations where it's been tested.
The effect size is large enough to matter clinically, not just statistically.
The intervention improves the primary outcome at standard doses in healthy adults.
The intervention improves the primary outcome at standard doses in healthy adults.
The effect size is large enough to matter clinically, not just statistically.
The headline effect shrinks once you account for trial quality.
The headline effect shrinks once you account for trial quality.
Animal-model results don't translate to the human protocol being recommended.
Animal-model results don't translate to the human protocol being recommended.
The headline effect shrinks once you account for trial quality.